SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) November 18, 1997
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission File Number) (IRS Employer
of incorporation) Identification No.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address,
if changes since last report.)
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On November 18, 1997, Biocontrol Technology, Inc. (NASDAQ:BICO)
announced today that the Company has repurchased $3 million in outstanding
debentures.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits-Press Release
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by
the undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper, CEO
DATED: November 18, 1997
BICO
BIOCONTROL TECHNOLOGY, INC
2275 Swallow Hill Road, Building 2500
Pittsburgh, PA 15220
Press Release
Release: Immediate
For More Information, Call:
Investors Media
Diane McQuaide Susan Taylor
1.412.429.0673 phone 1.412.279.9455 phone
1.412.279.9690 fax 1.412.279.9447 fax
BIOCONTROL TECHNOLOGY REDEEMS $3 MILLION IN DEBENTURES
Pittsburgh, PA - November 18, 1997 - Biocontrol Technology, Inc.
(Nasdaq:BICO) announced today that the Company has repurchased $3 million in
outstanding debentures. Chief Executive Officer Fred E. Cooper stated,
"Because management is convinced of the future success of Biocontrol
Technology, Inc. and its subsidiaries, our decision to repurchase the $3
million in debentures was made to protect the Company and its shareholders.
We feel very strongly that the Company is severely undervalued in light of our
future distribution in Manila of the Diasensor 1000 noninvasive glucose sensor
and the highly anticipated approval in Europe for the same product as well as
our ThermoChem System for HIV/AIDS and cancer treatment." Biocontrol
Technology, Inc. (www.bico.com) has its corporate offices in Pittsburgh, PA
and is involved in the development and manufacture of biomedical devices and
environmental products.
This press release contains statements of a forward looking nature.
Shareholders are cautioned that such statements are predictions and
that actual events or results may vary slightly.
